Month: September 2026

The Federal Circuit’s precedential decision in Exelixis, Inc. v. MSN Laboratories Private Ltd., Case No. 25-1236 (Fed. Cir. Aug. 31, 2026), affirmed a bench-trial finding that patents claiming crystalline cabozantinib (L)-malate satisfied the written-description requirement even though the specification expressly characterized only two crystalline polymorphs. The court concluded that the chemical name and formula of…